Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 16/20 | 0.81 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.59 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | IGF1R | P08069 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20214787 | 0.92 | MAP4K1 (0.84) | MAP4K1EGFRALKINSRIGF1R | |
| SCHEMBL24039985 | 0.92 | MAP4K1 (0.84) | MAP4K1EGFRALKINSRIGF1R | |
| SCHEMBL24040064 | 0.89 | MAP4K1 (1.00) | MAP4K1EGFRALKINSRIGF1R | |
| SCHEMBL24040086 | 0.89 | MAP4K1 (1.00) | MAP4K1EGFRALKINSRIGF1R | |
| SCHEMBL25338017 | 0.89 | MAP4K1 (0.65) | MAP4K1EGFRALKINSRIGF1R | |
| SCHEMBL20214415 | 0.88 | MAP4K1 (1.00) | MAP4K1ALKINSRIGF1R | |
| SCHEMBL24040082 | 0.88 | MAP4K1 (1.00) | MAP4K1ALKINSRIGF1R | |
| SCHEMBL24039954 | 0.88 | MAP4K1 (1.00) | MAP4K1EGFRALKINSRIGF1R | |
| SCHEMBL30184123 | 0.87 | MAP4K1 (0.63) | MAP4K1EGFRALK | |
| SCHEMBL24039922 | 0.87 | MAP4K1 (1.00) | MAP4K1ALKINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548479-A1 | ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS | ARIAD Pharmaceuticals, Inc. (US) | 2019-10-09 | — | — | EP | claimed |
| WO-2018102366-A1 | ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2018-06-07 | — | — | WO | claimed |
| WO-2022214008-A1 | HIGHLY ACTIVE HPK1 KINASE INHIBITOR | 杭州阿诺生物医药科技有限公司 | 2022-10-13 | — | — | WO | disclosed |
| US-11180482-B2 | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180482-B2 | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors | STK16, STK4, STK26 | MAP4K1 26/4885EGFR 1191/4885ALK 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.